$LIMN News

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Liminatus Pharma Regains Compliance With Nasdaq’s Minimum Bid Price Rule

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Liminatus Pharma Board Adopts Resolutions Approving Reverse Stock Split Of Its Common Stock At Ratio Of 1-For-50

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session (UPDATED)

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Liminatus Pharma Amends Proposed $320M Merger Deal With InnocsAI As Closing Now Anticipated Before Shareholder Approval On July 2

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Liminatus Pharma Enters Warrant Exercise Agreement With Existing Investors To Purchase 10,344,000 Shares At $0.18 Per Share

Liminatus Pharma Announces Nasdaq Delisting Notification

Liminatus Pharma Entered Definitive Agreement To Acquire InnocsAI On May 17 In $320M All-Stock Transaction

Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session

Liminatus Pharma Enters Merger Agreement With InnocsAI On May 17, 2026; InnocsAI Members To Receive 1.6B Shares At $0.20 Per Share And 20% Contingent Value Rights

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

Liminatus Intends To Start Phase 1 Clinical Study Of CD47-Blocking Monoclonal Antibody

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

Gold Down 3%; Medtronic Earnings Top Views